Latest news
Cell Therapy Weekly: RMAT Designation for Allogeneic CAR-T - RegMedNetRegMedNet · Fri, 31 Jul 2026 21:44:43 GMTFDA grants RMAT and fast track designation to cema-cel for first-line consolidation in MRD-positive LBCL - lymphomahub.comlymphomahub.com · Thu, 30 Jul 2026 19:46:39 GMTFDA Grants Fast Track and RMAT Designations to Cema-Cel in LBCL - Targeted OncologyTargeted Oncology · Thu, 30 Jul 2026 19:15:53 GMTCema-Cel Receives FDA RMAT, Fast Track Designations in First-Line LBCL - CancerNetworkCancerNetwork · Thu, 30 Jul 2026 15:07:19 GMTAllogene's Cema-Cel Receives FDA RMAT and Fast Track Designations for First-Line LBCL Consolidation - BioPharm InternationalBioPharm International · Wed, 29 Jul 2026 17:22:39 GMTFDA Grants RMAT and Fast Track Designations to Cema-Cel for First-Line LBCL - OncLiveOncLive · Wed, 29 Jul 2026 07:00:00 GMTAllogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma - Yahoo FinanceYahoo Finance · Wed, 29 Jul 2026 07:00:00 GMTAllogene Reports No Minimal Residual Disease in 7 of 12 Cema-Cel Patients - Stock TitanStock Titan · Wed, 29 Jul 2026 07:00:00 GMT